Detection and Monitoring in Fatty Liver Clinical Trials:
The Role of Medical Imaging

Dr. Mark Tengowski brings a large breadth of applied medical knowledge, critical thinking ability and drug development experience from compound nomination through post-marketing investigations to Bioclinica. In the industry since 1999, his imaging experience spans ultrastructural- and light-level microscopic evaluations to non-invasive imaging methods, applying imaging endpoints to nominate and advance compounds, manage safety findings and achieve regulatory approval. Mark serves as a medical advisor to the Business Development team, supporting new requests for clinical trials and consultation while being a scientific expert for projects with an inflammation or musculoskeletal focus (e.g., osteoarthritis, ankylosing spondylitis, NASH  Crohn’s disease, orphan diseases and more). With a veterinary background in inflammation and pharmacology, Mark approaches protocols from a mechanistic point of view – devising an imaging strategy that will achieve the study’s objective and end points.

Mark was previously invited to speak at the US Food and Drug Administration and is the author of several draft guidance issuances. He has given posters and podium presentations at national and international meetings, participated in several disease workshops and published numerous abstracts, articles and book chapters.  

Dr. Tengowski is a graduate of the University of Wisconsin-Madison and is licensed to practice veterinary medicine in WI and NY states, with USDA-accreditation, and is a member of the American College of Rheumatology.